A pharmaceutical composition comprising a compound capable of inhibiting the activity and / or expression of the CCR6 receptor for use as a medicament, wherein the compound capable of inhibiting the activity and / or expression of the CCR6 receptor is selected from the group consisting of the isolated polypeptide according to 1) or 2) and the expression vector according to 3) or 4), wherein 1) is an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of: (a) a sequence of amino acids that have at least 80% identity with the sequence according to SEQ ID NO .: 1； and (b) a fragment of the amino acid sequence according to (a)； wherein said isolated polypeptide is capable of binding to and inhibiting the activity of the CCR6 receptor； 2) is the polypeptide isolated according to 1), in which the amino acid sequence according to (a) comprises at least 8 consecutive amino acids of the sequence according to SEQ ID NO .: 1； 3) is an expression vector comprising an isolated polynucleotide encoding the polypeptide according to 1) or 2)； 4) is the expression vector comprising an isolated polynucleotide according to 3), wherein said polynucleotide comprises or consists of a sequence that has at least 80% identity with the sequence according to SEQ ID NO .: 4Una composición farmacéutica que comprende un compuesto capaz de inhibir la actividad y/o la expresión del receptor CCR6 para uso como medicamento, en la que el compuesto capaz de inhibir la actividad y/o la expresión del receptor CCR6 se selecciona del grupo que consiste en el polipéptido aislado según 1) ó 2) y el vector de expresión según 3) ó 4), en la que 1) es un polipéptido aislado que consiste en una secuencia de aminoácidos seleccionada del grupo que consiste en: (a) una secuencia de aminoácidos que presenta al menos 80% de identidad con la secuencia según SEQ ID NO.: 1； y (b) un fragmento de la secuencia de aminoácidos según (a)； en la que dicho polipéptido aislado es capaz d
